NOD1 and metabolic syndrome: Because of the recognized contributions of dyslipidemia and inflammation to insulin resistance, we sought to test if TKI-mediated inhibition of RIPK2 could attenuate NOD1-induced impairments in insulin signalling in adipocytes.